Indian stocks: Visit www.stage2stocks.com →

Bausch Health Companies Inc.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, Bausch Health Companies is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $6.49, 17.8% below its 52-week high and above its 200-day average, which is falling.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. More about the company

$6.49
+0.61% today
$2.4B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is BHC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S4 16w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 7w → S3 4w → S4 10w → S1 5w → S2 12w → S3 4w → S4 17w → S1 5w → S2 7w → S3 12w → S4 16w → S1 8w → S2 8w → S3 8w → S2 7w → S3 4w → S4 14w → S1 2w → S4 7w → S1 5w → S2 5w current
Total tracked: 165 weeks across 21 stage runs.

BHC among Drug Manufacturers - Specialty & Generic27th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…27BHCStage 2 · wk 659+13.7%
vs 52W High
-17.8%
$4.43 lo$7.90 hi
17.8% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
13.6%
200 DMA: $5.71 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.53x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+13.7%
3M
+46.5%
6M
+17.1%
YTD
-10.0%
1Y
+5.4%
Scan Membership
Breakout Watch
Latest: 2024-11-05
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 6 · Vol 0.53x
2026-10-21S2
Wk 6 · Vol 0.85x
2026-10-20S2
Wk 5 · Vol 0.89x
2026-10-19S2
Wk 5 · Vol 0.58x
2026-10-16S2
Wk 5 · Vol 0.93x
2026-10-15S2
Wk 5 · Vol 0.96x
2026-10-14S2
Wk 5 · Vol 0.65x
2026-10-13S2
Wk 4 · Vol 0.54x
2026-10-12S2
Wk 4 · Vol 0.78x
2026-10-09S2
Wk 4 · Vol 0.28x
2026-10-08S2
Wk 4 · Vol 0.35x
2026-10-07S2
Wk 4 · Vol 0.55x
Moving averages & range
50 DMA
$6.17
200 DMA
$5.71
52W High
$7.90
52W Low
$4.43
5D Low
$6.30
Resistance levels (recent highs)
20d High
$6.49
60d High
$7.00
120d High
$7.00
250d High
$7.90
Next resistance
+7.9%
to 60d High
Earnings Growth (YoY)
+70.4%
Revenue +12.7%
Dividend Yield
0.00%
P/B -1.4

Bausch Health Companies: quick answers

What stage is Bausch Health Companies in?

As of Oct 22, 2026, Bausch Health Companies (BHC) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Bausch Health Companies in an uptrend?

Yes. Bausch Health Companies is in a Stage 2 uptrend. It trades 13.6% above its 200-day average, which is falling.

How far is Bausch Health Companies from its 52-week high?

Bausch Health Companies closed at $6.49 on Oct 22, 2026, 17.8% below its 52-week high of $7.90. Its 52-week low is $4.43.

How has Bausch Health Companies performed over the past year?

As of Oct 22, 2026, Bausch Health Companies is up 5.4% over the past year and down 10.0% so far in 2026.

Which sector and industry is Bausch Health Companies in?

Bausch Health Companies is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.